Findings

What do systematic reviews say?

9 questions · 9 findings · 4 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 44.4%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 33.3%Moderate 1 · 11.1%High 1 · 11.1%

Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo

Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Scopolamine (hyoscine) patches vs placebo

Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Radiotherapy vs botulinum toxin

Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Botulinum toxin vs placebo

Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Low

Changes in quality of life (SIP) change in Sickness Impact Profile (SIP) scores (range from 0 = best health to 100 = worst health). · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
1 study · 503 participants
High

Non‐invasive ventilation vs usual care

Quality of life (SAQLI) · people with ALS

1 finding from 1 review

Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

Non‐invasive ventilation vs usual care

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · people with ALS

1 finding from 1 review

Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

Non‐invasive ventilation vs usual care

Quality of Life: SF‐36 (physical component) · people with ALS

The review found no eligible studies for this question.

1 finding from 1 review

Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life Short Form 12 Health Survey (SF‐12) · people with ALS/MND

1 finding from 1 review

Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 128 participants
Moderate